Caricamento...
Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma
Current treatments for glioblastoma multiforme (GBM)—an aggressive form of brain cancer—are minimally effective and yield a median survival of 14.6 months and a two-year survival rate of 30%. Given the severity of GBM and the limitations of its treatment, there is a need for the discovery of novel d...
Salvato in:
| Pubblicato in: | PLoS One |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Public Library of Science
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5771580/ https://ncbi.nlm.nih.gov/pubmed/29342193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0190664 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|